Two-Staged Bronchoscopic Lung Volume Reduction: A Single US Academic Center Retrospective Analysis Demonstrating Reduction in Pneumothorax.

IF 0.8 Q4 RESPIRATORY SYSTEM

Respirology Case Reports Pub Date : 2025-09-22 eCollection Date: 2025-09-01 DOI:10.1002/rcr2.70355

Chih-Huan Lu, Brooks T Kuhn, Michael Schivo, Chinh Phan, Ken Y Yoneda, Jeremy J Kim

{"title":"Two-Staged Bronchoscopic Lung Volume Reduction: A Single US Academic Center Retrospective Analysis Demonstrating Reduction in Pneumothorax.","authors":"Chih-Huan Lu, Brooks T Kuhn, Michael Schivo, Chinh Phan, Ken Y Yoneda, Jeremy J Kim","doi":"10.1002/rcr2.70355","DOIUrl":null,"url":null,"abstract":"<p><p>Staged Bronchoscopic lung volume reduction (BLVR) has been proposed to reduce the risk of pneumothorax in patients with emphysema, though evidence to date is limited. We present a retrospective series from a single US academic centre, evaluating pneumothorax and other complications following staged BLVR. Seventeen patients underwent staged BLVR at our centre. Two illustrative cases are presented: (1) a case of pneumothorax post-staged BLVR managed conservatively without chest tube insertion, and (2) a patient who initially developed pneumothorax after single-stage BLVR, subsequently completing staged BLVR without complications. Overall, the pneumothorax rate within 45 days was 11.8%, and none of the events required tube drainage or valve removal. This retrospective analysis suggests that staged BLVR may reduce the incidence of pneumothorax. Larger, randomised controlled trials are warranted to confirm these potential benefits.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"13 9","pages":"e70355"},"PeriodicalIF":0.8000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454916/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Staged Bronchoscopic lung volume reduction (BLVR) has been proposed to reduce the risk of pneumothorax in patients with emphysema, though evidence to date is limited. We present a retrospective series from a single US academic centre, evaluating pneumothorax and other complications following staged BLVR. Seventeen patients underwent staged BLVR at our centre. Two illustrative cases are presented: (1) a case of pneumothorax post-staged BLVR managed conservatively without chest tube insertion, and (2) a patient who initially developed pneumothorax after single-stage BLVR, subsequently completing staged BLVR without complications. Overall, the pneumothorax rate within 45 days was 11.8%, and none of the events required tube drainage or valve removal. This retrospective analysis suggests that staged BLVR may reduce the incidence of pneumothorax. Larger, randomised controlled trials are warranted to confirm these potential benefits.

查看原文本刊更多论文

两阶段支气管镜下肺体积缩小：一项美国学术中心回顾性分析显示气胸减少。

分期支气管镜肺减容术（BLVR）已被建议用于降低肺气肿患者气胸的风险，尽管迄今为止证据有限。我们介绍了一个美国学术中心的回顾性研究，评估了分期BLVR后的气胸和其他并发症。17例患者在本中心分期行BLVR。本文提出了两个说白了的病例：(1)一例气胸分期BLVR后保守处理，未插入胸管；(2)一名患者在单期BLVR后最初出现气胸，随后完成分期BLVR，无并发症。总的来说，45天内的气胸发生率为11.8%，没有任何事件需要引流或移除瓣膜。本回顾性分析提示分期BLVR可减少气胸的发生率。需要更大规模的随机对照试验来证实这些潜在的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.